AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China
AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list...
NYSE: ABBV
AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs
AbbVie Inc. (NYSE: ABBV) announced today that it will terminate its long‑standing collaboration agreement with...
AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges
U.S. biopharma leader AbbVie Inc. (NYSE: ABBV) released its third‑quarter fiscal‑2025 results. Net revenues rose...
AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA
AbbVie (NYSE: ABBV) announced positive topline data from its Phase IIIb/IV head‑to‑head trial, SELECT‑SWITCH, comparing upadacitinib...
AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma
American pharmaceutical giant AbbVie (NYSE: ABBV) disclosed that its bispecific T‑cell engager, epcoritamab, has been...
AbbVie Acquires Bretisilocin from Gilgamesh in $1.2B Deal for MDD Treatment
American pharmaceutical giant AbbVie (NYSE: ABBV) has finalized a definitive agreement to acquire bretisilocin, an...
AbbVie Reports Strong Q2 2025 Results With Immunology Portfolio Leading Growth
US-based multinational AbbVie Inc. (NYSE: ABBV) reported strong Q2 2025 results with global revenues increasing...
AbbVie Licenses IGI Therapeutics’ ISB 2001 for Oncology and Autoimmune Diseases
US-based AbbVie (NYSE: ABBV) this week announced a licensing agreement with IGI Therapeutics SA, a...
AbbVie’s Venclexta Approved by China’s NMPA for CLL/SLL Patients with 17p Deletion
US-based major AbbVie Inc., (NYSE: ABBV) announced that it has received marketing approval from China’s...
Allergan Aesthetics’ SKINVIVE by JUVÉDERM Accepted for FDA Review to Reduce Neck Lines
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that the supplemental premarket approval (sPMA) application...
AbbVie to Acquire Capstan Therapeutics for Its First-in-Class CAR-T Candidate
US-based pharmaceutical giant AbbVie (NYSE: ABBV) is poised to acquire fellow American firm Capstan Therapeutics,...
Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming announced the first patient dosing...
AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial
US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...
AbbVie’s Mavyret Gains FDA Approval for Acute HCV in Children and Adults
US-based AbbVie (NYSE: ABBV) announced that the US Food and Drug Administration (FDA) has approved...
AbbVie’s Emrelis Granted FDA Accelerated Approval for NSCLC with High c-MET Overexpression
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AbbVie’s (NYSE: ABBV)...
AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics
US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals,...
AbbVie Files BLA for TrenibotE in Moderate to Severe Glabellar Lines Treatment
US-based AbbVie (NYSE: ABBV) announced that it has filed a Biologics License Application (BLA) with...
AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...
AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development
US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court...
AbbVie’s Skyrizi Approved by China’s NMPA for Moderate to Severe Crohn’s Disease
US giant AbbVie (NYSE: ABBV) announced receiving marketing approval from China’s National Medical Products Administration...